雌激素受体与L1细胞黏附分子表达对子宫内膜癌结局的影响与临床病理风险组及分子亚组相关
本研究回顾性分析1044例子宫内膜癌患者,按欧洲指南分为5个临床病理风险组并行分子分型,评估ER与L1CAM表达的预后价值。中位随访67.5个月,ER与L1CAM的预后意义因风险组和分子亚组而异;在高危-晚期-转移性NSMP和MMRd癌中,ER状态可细化风险评估。
要点
- 在NSMP亚组中,ER表达与疾病特异性生存改善相关(P<0.001),L1CAM阴性亦与DSS改善相关(P<0.001)。
- 控制诊断时参数后,NSMP中ER(HR 0.18)有预后意义,L1CAM无。
- 高危-晚期-转移性病例中,ER(HR 0.26)与L1CAM(HR 3.9)均独立相关于DSS。
核心结论
- ER和L1CAM的预后意义在子宫内膜癌不同临床病理风险组和分子亚组间存在差异。
- 高危-晚期-转移性NSMP和MMRd亚型癌的风险评估可通过ER状态得到细化。
研究设计与样本
- 回顾性研究,纳入单中心初始治疗的患者1044例,按欧洲指南分为5个临床病理风险组,行免疫组化和POLE测序进行分子分型及ER、L1CAM表达检测,中位随访67.5个月。
主要发现
- 单因素分析中,ER表达与NSMP亚组(P<0.001)和MMRd亚组(P=0.002)的DSS改善相关。
- L1CAM阴性仅与NSMP亚组的DSS改善相关(P<0.001)。
- 控制诊断时可用参数(肿瘤组织学类型、分级、年龄)后,NSMP中ER(HR 0.18)有预后意义,L1CAM无。
- 控制术后可用参数(临床病理风险组、年龄、辅助治疗)后,NSMP中ER和L1CAM均未独立相关于DSS。
- 高危-晚期-转移性病例中,ER(HR 0.26)和L1CAM(HR 3.9)均独立相关于DSS;MMRd中高危-晚期-转移性癌的ER与DSS改善相关(HR 0.42)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk stratification of clinicopathologically and molecularly classified endometrial cancer based on estrogen receptor (ER) and L1 cell adhesion molecule (L1CAM) expression. METHODS: This was a retrospective study of patients who underwent primary treatment at a single tertiary center. Carcinomas were classified into 5 clinicopathological risk groups, as per European guidelines. Immunohistochemistry and polymerase-ϵ sequencing were conducted for molecular classification and determination of ER and L1CAM expression. RESULTS: Data from 1044 patients were analyzed. The median follow-up was 67.5 months. In univariable analyses, ER expression correlated with improved disease-specific survival (DSS) in the "no specific molecular profile" (NSMP) (P < 0.001) and mismatch repair deficient (MMRd) (P = 0.002) subgroups. Negative L1CAM expression was associated with enhanced DSS in the NSMP subgroup alone (P < 0.001). ER (hazard ratio [HR] 0.18), but not L1CAM, exhibited prognostic significance within NSMP when controlling for parameters available at the time of diagnosis (tumor histotype, grade, age). ER and L1CAM were not independently associated with DSS within NSMP when controlling for parameters available after surgery (clinicopathological risk groups, age, adjuvant therapy). However, in high-risk-advanced-metastatic cases, both ER (HR 0.26) and L1CAM (HR 3.9) independently correlated with DSS. Similarly, within MMRd, ER was associated with improved DSS in high-risk-advanced-metastatic carcinomas (HR 0.42). CONCLUSION: The prognostic significance of ER and L1CAM varies across clinicopathological risk groups and molecular subgroups of endometrial cancer. Notably, risk assessment for high-risk-advanced-metastatic NSMP and MMRd subtype carcinomas can be refined by ER status.
引用
- Aro K, Pasanen A, Bützow R, et al. The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup. Gynecol Oncol. 2024. PMID: 38972089. doi:10.1016/j.ygyno.2024.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。